Invus logo

Invus

North America, New York, United States, New York

Description

Invus is a private equity and venture capital firm established in 1985, headquartered in New York City. The firm is renowned for its highly flexible, long-term investment approach, which eschews formulaic strategies in favor of deeply understanding and supporting unique businesses. Invus operates with a sector-agnostic mandate, though it has built a particularly strong track record in consumer products, healthcare, technology, and food and beverage industries. Their philosophy centers on partnering with exceptional management teams to build enduring companies, often providing patient capital over extended periods.

Invus typically invests across various stages, from early-stage venture capital to significant growth equity and even buyouts. They are known for their willingness to take both minority and control stakes, adapting their investment structure to best suit the needs of the company. The firm emphasizes providing strategic guidance and operational support, leveraging its extensive network and experience to help portfolio companies scale and achieve their full potential. This hands-on, yet non-prescriptive, involvement is a hallmark of their partnership model.

The firm manages over $10 billion in capital, enabling them to make substantial commitments to their portfolio companies. Their investment sizes can vary widely, reflecting their flexible approach, but typical first checks for growth equity opportunities often range from tens of millions to hundreds of millions of dollars. Invus has built an extensive portfolio comprising over 100 investments, demonstrating their broad reach and consistent activity in the private markets. Their enduring presence and substantial capital base position them as a significant and patient partner for companies seeking long-term growth.

Investor Profile

Invus has backed more than 253 startups, with 22 new investments in the last 12 months alone. The firm has led 47 rounds, about 19% of its total and boasts 70 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series C, Post Ipo Equity rounds (top funding stages).
  • Majority of deals are located in United States, France, Switzerland.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.
  • Led 3 rounds in the past year.
  • Typical check size: $20M – $250M.

Stage Focus

  • Series B (24%)
  • Series C (17%)
  • Post Ipo Equity (17%)
  • Series A (16%)
  • Series Unknown (13%)
  • Series D (6%)
  • Series E (2%)
  • Private Equity (2%)
  • Seed (1%)
  • Convertible Note (1%)

Country Focus

  • United States (74%)
  • France (7%)
  • Switzerland (3%)
  • United Kingdom (2%)
  • China (2%)
  • Sweden (2%)
  • Finland (2%)
  • Ireland (1%)
  • Canada (1%)
  • Jordan (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Life Science
  • Pharmaceutical
  • Biopharma
  • Software
  • Genetics
  • Information Technology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Invus frequently co-invest with?

EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 20
OrbiMed
North America, New York, United States, New York
Co-Investments: 22
Samsara BioCapital
North America, California, United States, Palo Alto
Co-Investments: 20
Casdin Capital
North America, New York, United States, New York
Co-Investments: 24
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 27
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 23
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 21
Redmile Group
North America, California, United States, San Francisco
Co-Investments: 20
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 23
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 35

Which angels does Invus often collaborate with?

GF
North America, California, United States
Shared Deals: 2
JN
North America, California, United States, Los Angeles
Shared Deals: 1
AG
North America, New Jersey, United States, New Brunswick
Shared Deals: 1
AB
North America, California, United States, Los Angeles
Shared Deals: 1
NG
North America, California, United States, San Francisco
Shared Deals: 1
JR
North America, California, United States, San Francisco
Shared Deals: 1
TA
North America, Massachusetts, United States, Cambridge
Shared Deals: 3
PM
North America, Massachusetts, United States, Cambridge
Shared Deals: 2

What are some of recent deals done by Invus?

One Biosciences

Paris, Ile-de-France, France

One Biosciences leverages single-cell technologies to identify new therapeutics for difficult-to-treat diseases.

BiotechnologyLife ScienceTherapeutics
Series AJul 17, 2025
Amount Raised: $17,385,761
Aive

Levallois-perret, Ile-de-France, France

AI video platform for large-scale video automation

Artificial Intelligence (AI)Information TechnologyMachine LearningVideo
Series AJun 5, 2025
Amount Raised: $13,692,378
Edgewise Therapeutics

Boulder, Colorado, United States

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

BiopharmaBiotechnologyHealth Care
Post Ipo EquityApr 2, 2025
Amount Raised: $200,000,000
GenSight Biologics

Paris, Ile-de-France, France

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.

BiotechnologyGeneticsHealth CareMedical
Post Ipo EquityMar 7, 2025
Amount Raised: $932,723
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityMar 4, 2025
Amount Raised: $100,000,000
Solid Biosciences

Marlborough, Massachusetts, United States

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

BiotechnologyGeneticsHealth CareMedical
Post Ipo EquityFeb 18, 2025
Amount Raised: $200,000,000
Bambusa Therapeutics

Boston, Massachusetts, United States

Bambusa Therapeutics operates as biotechnology company.

BiotechnologyHealth CareLife ScienceMedical
Series AFeb 14, 2025
Amount Raised: $90,000,000
Dorsia

Miami Beach, Florida, United States

Dorsia is a members-only platform that offers reservations at in-demand restaurants in major cities

Online PortalsReservationsRestaurantsSoftware
Series AFeb 14, 2025
Amount Raised: $50,400,000
Call Your Mother

Washington, District of Columbia, United States

Call Your Mother is the place where good food, service, and fun make for a great experience.

BakeryCoffeeFood and BeverageRestaurants
Secondary MarketJan 13, 2025
Coave Therapeutics

Paris, Ile-de-France, France

Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.

BiotechnologyGeneticsLife ScienceNeuroscience
Series AJan 9, 2025
Amount Raised: $32,948,556